Company Overview
Aardvark is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways to alleviate hunger for the treatment of metabolic diseases. Targeting Bitter Taste Receptors (TAS2Rs) expressed in the gut lumen, our lead product candidate, ARD-101, has entered Phase 3 development for hyperphagia associated with Prader-Willi Syndrome and is being evaluated for hyperphagia associated with hypothalamic obesity, with a goal of addressing significant unmet needs across both these rare disease indications. We are also developing ARD-201, which will be a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions.